Sei Investments Co. Acquires New Shares in Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

Sei Investments Co. bought a new position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 69,702 shares of the company’s stock, valued at approximately $100,000. Sei Investments Co. owned about 0.09% of Tenaya Therapeutics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TNYA. SG Americas Securities LLC increased its holdings in Tenaya Therapeutics by 61.9% in the fourth quarter. SG Americas Securities LLC now owns 41,270 shares of the company’s stock worth $59,000 after buying an additional 15,777 shares during the last quarter. State Street Corp increased its stake in shares of Tenaya Therapeutics by 0.9% during the 3rd quarter. State Street Corp now owns 1,058,898 shares of the company’s stock worth $2,044,000 after purchasing an additional 9,506 shares during the last quarter. Spire Wealth Management bought a new position in shares of Tenaya Therapeutics during the 4th quarter valued at $53,000. Geode Capital Management LLC lifted its stake in shares of Tenaya Therapeutics by 5.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,296,156 shares of the company’s stock valued at $2,502,000 after purchasing an additional 66,968 shares during the last quarter. Finally, XTX Topco Ltd boosted its holdings in Tenaya Therapeutics by 51.2% in the third quarter. XTX Topco Ltd now owns 49,290 shares of the company’s stock worth $95,000 after purchasing an additional 16,687 shares in the last quarter. 90.54% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, major shareholder Group Gp Lp Column III bought 35,714,284 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The stock was acquired at an average cost of $0.70 per share, for a total transaction of $24,999,998.80. Following the completion of the purchase, the insider now owns 49,313,559 shares of the company’s stock, valued at $34,519,491.30. This trade represents a 262.62 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold 19,621 shares of company stock worth $10,595 in the last ninety days. Insiders own 32.76% of the company’s stock.

Tenaya Therapeutics Stock Up 12.0 %

TNYA opened at $0.49 on Friday. The stock’s 50 day moving average price is $0.74 and its two-hundred day moving average price is $1.56. The firm has a market capitalization of $43.17 million, a P/E ratio of -0.34 and a beta of 2.98. Tenaya Therapeutics, Inc. has a 12-month low of $0.39 and a 12-month high of $4.96.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings data on Monday, March 17th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.04. As a group, analysts anticipate that Tenaya Therapeutics, Inc. will post -1.35 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have weighed in on TNYA shares. Chardan Capital reduced their price target on Tenaya Therapeutics from $18.00 to $9.00 and set a “buy” rating for the company in a research report on Wednesday, March 12th. HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of Tenaya Therapeutics in a report on Monday, March 31st. Canaccord Genuity Group decreased their target price on Tenaya Therapeutics from $18.00 to $6.00 and set a “buy” rating for the company in a research report on Thursday, March 13th. Finally, Morgan Stanley dropped their price target on shares of Tenaya Therapeutics from $15.00 to $5.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 12th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $6.25.

Tenaya Therapeutics Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.